Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers [PDF]
, 2021 Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Onno A. Spruijt +31 more
core +1 more source
Megakaryocytes in the Pulmonary Circulation [PDF]
Blood, 1963 Abstract The streptolysin 0 hemolysis method for isolation of cancer cells in the blood was employed for direct observations of the incidence and some characteristics of circulating megakaryocytes. In a series of 168 patients, circulating megakaryocytes were found in 77 per cent of the blood samples.
T M, SCHEININ, A P, KOIVUNIEMI
openaire +2 more sources
Frontiers in Cardiovascular Medicine, 2021 Background: Right ventricular (RV) function is a great determination of the fate in patients with pulmonary arterial hypertension (PAH). Monitoring RV structure back to normal or improvement should be useful for evaluation of RV function.
Qin-Hua Zhao +11 more
doaj +1 more source
Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy [PDF]
, 2017 Pulmonary arterial hypertension (PAH) is a progressive and debilitating condition. Despite promoting vasodilation, current drugs have a therapeutic window within which they are limited by systemic side effects.
Lickiss, PD +17 more
core +1 more source
Exosomal circular RNAs: Biogenesis, effect, and application in cardiovascular diseases
Frontiers in Cell and Developmental Biology, 2022 As natural nanoparticles, exosomes regulate a wide range of biological processes via modulation of its components, including circular RNAs (circRNAs).
Xiaoyi Hu +15 more
doaj +1 more source
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. [PDF]
, 2005 BACKGROUND: Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur.
Shakur, B Haleema +17 more
core +1 more source
Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism
Animal Models and Experimental Medicine, 2022 Circular RNAs (circRNAs) are endogenous RNAs with a covalently closed single‐stranded transcript. They are a novel class of genomic regulators that are linked to many important development and disease processes and are being pursued as clinical and ...
Qian Wang +6 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2022 Background We recently demonstrated that circGSAP was diminished in lung tissues from patients with pulmonary arterial hypertension and in hypoxia-induced pulmonary microvascular endothelial cells (PMECs).
Yuanyuan Sun +11 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 ObjectiveWhether exercise-induced venous-to-systemic shunt (EIS) during cardiopulmonary exercise testing (CPET) has different manifestations or characteristics in idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary ...
Shang Wang +15 more
doaj +1 more source
Biology and function of pericytes in the vascular microcirculation
Animal Models and Experimental Medicine, 2023 Pericytes are the main cellular components of tiny arteries and capillaries. Studies have found that pericytes can undergo morphological contraction or relaxation under stimulation by cytokines, thus affecting the contraction and relaxation of ...
Yue Wu +12 more
doaj +1 more source